Companhia Siderúrgica Nacional

Seeking Alpha•7/23/2026

Companhia Siderurgica Nacional: The Deleveraging Thesis Has Turned Into A Value Trap

LG Display reveals experimental study results on Gaming OLED performance

LG Display reveals experimental study results on Gaming OLED performance PR Newswire SEOUL, South Korea, July 8,

SciBase Announces New Research Highlighting Nevisense's Potential in Detecting Age-Related Skin Barrier Changes

SciBase Announces New Research Highlighting Nevisense's Potential in Detecting Age-Related Skin Barrier Changes PR Newswire

Zacks Investment Research•5/15/2026

National Steel Q1 Earnings Miss Estimates on Softer Steel Demand

SID incurs a loss in Q1 as softer steel demand, imports and weather drag revenues, though EBITDA rises and margins improve.

National Steel Q1 Earnings Call Highlights

National Steel NYSE: SID, the Brazilian steelmaker known as CSN, reported higher first-quarter 2026 adjusted EBITDA despite heavy rainfall, a stronger Brazilian real and continued pressure from steel imports in the early part of the year, executives said on the company's earnings call.

Seeking Alpha•5/14/2026

Companhia Siderúrgica Nacional (SID) Q1 2026 Earnings Call Transcript

GlobeNewsWire•5/14/2026

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib's novel mechanism of action and clinical results SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif.

GlobeNewsWire•5/5/2026

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company's novel oncolytic peptide, VP-315 (ruxotemitide), in the treatment of basal cell carcinoma (BCC) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, taking place from May 13-16, 2026, in Chicago, Illinois.

LG Display presents future of displays with next-generation OLED technologies at SID Display Week 2026

SEOUL, South Korea, May 4, 2026 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today that it is unveiling its next-generation OLED technologies at SID Display Week 2026, further strengthening its OLED leadership. During the exhibition, held at the Los Angeles Convention Center from May 5 to 7, LG Display will present OLED display solutions optimized for the AI era under the theme, "OLED Evolution for the AI Era.

CSN announces its Annual Report on Form 20-F for the fiscal year ended December 31, 2025

SÃO PAULO, April 30, 2026 /PRNewswire/ -- Companhia Siderúrgica Nacional (NYSE: SID and B3: CSNA3) ("CSN") has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on April 30, 2026. Shareholders and holders of American depositary shares representing CSN's shares have the ability to, upon request to CSN's Investor Relations Department, receive a hard copy of CSN's complete audited financial statements, free of charge, within a reasonable period of time following the request.